Holen Sie sich die Stockscreener-App
735.20
0.05%
0.39
Handel nachbörslich:
736.50
1.30
+0.18%
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent - MedCity News
Baird reiterates Regeneron stock rating on Sanofi collaboration By Investing.com - Investing.com Canada
Sanofi To Pay Regeneron Up To $8B In Immunology Alliance - Law360
REGN Maintained by Jefferies -- Price Target Raised to $930 - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 - MarketBeat
Sanofi Commits Up to $8 Billion to Expand Regeneron Alliance on Next-Gen Antibodies - finance.biggo.com
Regeneron stock after-hours at EUR 660.45: minus 1.31 percent versus prior close - AD HOC NEWS
Jefferies raises Regeneron stock price target to $930 on partnership By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr - GuruFocus
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri - GuruFocus
Why Regeneron (REGN) Stock Is Trading Lower Today - FinancialContent
Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG - GuruFocus
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Sanofi and Regeneron expand global alliance - The Pharma Letter
Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients - TradingView
Sanofi to ‘ignite’ R&D in $8B deal with longstanding partner Regeneron - BioWorld News
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) - The Manila Times
Regeneron reports 73% response rate for ovarian cancer drug trial By Investing.com - Investing.com Canada
Sanofi, Regeneron broaden alliance to find their next Dupixent - Yahoo Finance
Patients in a small study had a median 11 months without ovarian cancer worsening on an experimental drug. - Stock Titan
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss - marketscreener.com
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal - WSJ
BMO reiterates Regeneron stock Outperform on Sanofi deal expansion By Investing.com - Investing.com Canada
Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion - Benzinga
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion - MarketBeat
REGN: Expanded alliance targets next-gen type 2 medicines with equal cost/profit sharing and $8B in payments - TradingView
REGN Upgraded by Argus Research -- Price Target Announced at $85 - GuruFocus
Argus upgrades Regeneron stock to Buy with USD 850 target - AD HOC NEWS
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor - biospace.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus - MarketBeat
Upcoming Webinar Hosted by Xtalks: Inside Regeneron's Path to Scientific Intelligence and R&D Efficiency - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts - Yahoo Finance
Argus upgrades Regeneron stock rating to buy on Dupixent growth By Investing.com - Investing.com Canada
BreakingviewsCOMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A - reuters.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
Sanofi and Regeneron expand immunology partnership to the tune of $8bn - Pharmaceutical Technology
Sanofi to invest up to $8bn to expand alliance with Regeneron - marketscreener.com
REGN Stock In Focus: Sanofi Expands Immunology Deal With $1B Upfront Payment And 4 New Antibodies - Stocktwits
Sanofi expands Regeneron partnership with up to $8 billion deal i - Global Banking & Finance Review
Sanofi Expands Collaboration with Regeneron in Immunology with $10 Billion Upfront Payment - GuruFocus
Regeneron, Sanofi expand alliance with $1 billion upfront deal By Investing.com - Investing.com Canada
Regeneron drug said to cut muscle loss when combined with Novo's semaglutide (REGN:NASDAQ) - Seeking Alpha
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion - Yahoo Finance
Sanofi and Regeneron Expand Antibody Collaboration - marketscreener.com
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - marketscreener.com
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies - The Manila Times
Regeneron and Sanofi Expand Long-Standing Collaboration to Add Next-Generation Long-Acting Immunology Antibodies in Deal Worth Up to $8 Billion - Quiver Quantitative
REGN: Expanded partnership targets next-gen immunology therapies, sharing costs, profits, and innovation - TradingView
Regeneron (REGN) Grants One-Time Performance Awards to CEO and CSO, Forms New Subsidiary - GuruFocus
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com
Regeneron’s ALN-F1202 Safety Trial Marks a Quiet but Important Pipeline Milestone - TipRanks
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18 - MarketBeat
What Is Regeneron Pharmaceuticals (REGN) Facing After A Rival Matched Its Key Eye Drug? - Simply Wall Street
REGN Reiterates by RBC Capital -- Price Target Maintained at $73 - GuruFocus
Royal Bank Of Canada Reaffirms "Sector Perform" Rating for Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
RBC Capital reiterates Sector Perform rating on Regeneron Pharmaceuticals, $737 price target - TradingView
Regeneron stock falls 4.54 percent to USD 752.25 ahead of earnings - AD HOC NEWS
Regeneron stock at USD 752.25 on September 28, 2026 - AD HOC NEWS
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? - The Motley Fool
Why Is Regeneron Pharmaceuticals Stock Falling Today?Regeneron Pharmaceuticals (NASDAQ:REGN), Kodiak S - Benzinga
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine - Benzinga
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Benzinga
Regeneron stock at USD 788.04 on September 25, 2026, down 1.00 percent - AD HOC NEWS
Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN) - The Globe and Mail
REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. InvestorsLead Plaintiff Deadline September 14, 2026 - ACCESS Newswire
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine
0.57%
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):